Post by account_disabled on Jan 11, 2024 3:15:04 GMT -5
The Butantan Institute announced this Thursday that it is developing a vaccine against the Zika virus, which can cause microcephaly in babies when the infection occurs during pregnancy. The immunizer is composed of the inactivated virus, a platform classified by the institute as ideal and safest for use in pregnant women. The expectation is that animal testing will begin in the second half of . “Researchers have been dedicated to studying
The vaccine since when Brazil faced an epidemic of the virus”, highlighted . Data from the Ministry of Health show that, between the country registered almost cases of congenital microcephaly. Continues after advertising - “Proof-of-concept studies carried out on Europe Cell Phone Number List animals to assess the viability of the product, have already shown that the vaccine is capable of generating neutralizing antibodies against Zika. The next stage, scheduled for August is to
Carry out pre-clinical safety tests to check tolerability and possible adverse reactions”, highlighted . “Although it is still in its initial phase, expectations regarding the new vaccine candidate are positive. It uses classic production techniques, in addition to a traditional adjuvant, aluminum hydroxide (a compound responsible for enhancing the response and helping to maintain it in the long term). These are known methods and considered safe by the scientific community.
The vaccine since when Brazil faced an epidemic of the virus”, highlighted . Data from the Ministry of Health show that, between the country registered almost cases of congenital microcephaly. Continues after advertising - “Proof-of-concept studies carried out on Europe Cell Phone Number List animals to assess the viability of the product, have already shown that the vaccine is capable of generating neutralizing antibodies against Zika. The next stage, scheduled for August is to
Carry out pre-clinical safety tests to check tolerability and possible adverse reactions”, highlighted . “Although it is still in its initial phase, expectations regarding the new vaccine candidate are positive. It uses classic production techniques, in addition to a traditional adjuvant, aluminum hydroxide (a compound responsible for enhancing the response and helping to maintain it in the long term). These are known methods and considered safe by the scientific community.